VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LFCR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
LFCRLifecore Biomedical, Inc.
$4.96$186M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksLFCRFinancials

Lifecore Biomedical, Inc. (LFCR) Financials

29Y historyFree accessUpdated daily

Revenue volatility remains a critical concern, with the company reporting a 34.0% year-over-year decline in 2026Q3 alongside a sharp contraction in gross margins to 19.2%.

LFCR Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMMay'25May'24May'23May'22May'21May'20May'19May'18May'17May'16May'15May'14May'13May'12May'11May'10May'09May'08May'07May'06May'05May'04Oct'02Oct'01Oct'00Oct'99Oct'98Oct'97Oct'96
Sales/Revenue135.16M128.87M128.26M103.27M111.27M100.87M160.07M557.56M524.23M532.26M541.1M539.26M476.81M441.71M317.55M276.73M238.22M235.94M238.53M210.5M231.95M205.23M192.09M183.16M190.88M209.55M35.4M33.5M9.5M2.5M
Revenue Growth %3.72%0.47%24.2%-7.19%10.31%-36.98%-71.29%6.36%-1.51%-1.63%0.34%13.1%7.95%39.1%14.75%16.16%0.97%-1.09%13.32%-9.25%13.02%6.84%4.88%-4.05%-8.91%491.95%5.67%252.63%280%-
Cost of Goods Sold93.03M88.57M86.41M75.28M72.2M61.94M120.68M476.56M445.89M449.07M470.14M473.85M414.25M378.95M265.41M230.03M204.46M201.66M200.3M178.11M191.91M173.26M162.3M151.81M163.29M170.12M19.3M18.2M5.1M500K
COGS % of Revenue-68.73%67.37%72.9%64.89%61.4%75.39%85.47%85.06%84.37%86.89%87.87%86.88%85.79%83.58%83.13%85.83%85.47%83.97%84.61%82.74%84.42%84.49%82.89%85.55%81.18%54.52%54.33%53.68%20%
Gross Profit42.13M40.3M41.85M27.98M39.07M38.94M39.39M81M78.34M83.19M70.96M65.41M62.56M62.76M52.14M46.7M33.77M34.28M38.23M32.39M40.04M31.97M29.79M31.34M27.59M39.43M16.1M15.3M4.4M2M
Gross Margin %31.17%31.27%32.63%27.1%35.11%38.6%24.61%14.53%14.94%15.63%13.11%12.13%13.12%14.21%16.42%16.87%14.17%14.53%16.03%15.39%17.26%15.58%15.51%17.11%14.45%18.82%45.48%45.67%46.32%80%
Gross Profit Growth %--3.71%49.54%-28.36%0.33%-1.14%-51.38%3.4%-5.83%17.23%8.49%4.54%-0.31%20.37%11.66%38.29%-1.5%-10.33%18.04%-19.12%25.25%7.32%-4.94%13.6%-30.03%144.89%5.23%247.73%120%-
Operating Expenses42.21M57.54M50.69M49.78M50.86M47.76M65.26M75.53M64.75M67.68M56.74M46.95M42.37M37.89M36.14M33.88M22.06M21.68M23.05M2.02M31.02M25.95M25.74M30.08M30.24M39.64M19.2M18.6M13.4M7.6M
OpEx % of Revenue-44.65%39.52%48.21%45.71%47.35%40.77%13.55%12.35%12.72%10.49%8.71%8.89%8.58%11.38%12.24%9.26%9.19%9.66%0.96%13.37%12.65%13.4%16.42%15.84%18.92%54.24%55.52%141.05%304%
Selling, General & Admin33.33M44.05M40.46M38.97M34.66M27.72M40.67M64.06M51.95M58.21M49.52M39.96M35.17M32.53M26.52M24.61M17.7M18.02M19.8M21.62M27.98M23.41M22M26.42M26.97M28.88M11.2M10.8M4.7M3.3M
SG&A % of Revenue-34.18%31.55%37.74%31.15%27.48%25.41%11.49%9.91%10.94%9.15%7.41%7.38%7.36%8.35%8.89%7.43%7.64%8.3%10.27%12.06%11.41%11.45%14.42%14.13%13.78%31.64%32.24%49.47%132%
Research & Development7.58M8.26M8.57M8.74M7.84M6.68M7.58M11.47M12.8M9.47M7.23M6.99M7.2M9.29M9.63M9.28M4.36M3.67M3.25M3.07M3.04M2.54M3.73M3.66M3.27M4.7M5.8M5.7M7.6M3.8M
R&D % of Revenue-6.41%6.69%8.46%7.04%6.63%4.74%2.06%2.44%1.78%1.34%1.3%1.51%2.1%3.03%3.35%1.83%1.55%1.36%1.46%1.31%1.24%1.94%2%1.71%2.24%16.38%17.01%80%152%
Other Operating Expenses05.24M1.66M2.08M8.36M13.36M17.01M00-333K0008.1M00000-22.67M000006.07M2.2M2.1M1.1M500K
Operating Income-78K-17.25M-8.84M-21.8M-11.79M-8.82M-25.88M-8.01M11.85M15.51M-19.79M18.46M20.19M24.87M14.58M8.03M11.71M12.6M15.18M30.36M9.02M6.02M4.05M1.26M-2.65M-213K-3.1M-3.3M-9M-5.6M
Operating Margin %-0.06%-13.38%-6.9%-21.11%-10.6%-8.75%-16.17%-1.44%2.26%2.91%-3.66%3.42%4.23%5.63%4.59%2.9%4.91%5.34%6.36%14.43%3.89%2.93%2.11%0.69%-1.39%-0.1%-8.76%-9.85%-94.74%-224%
Operating Income Growth %--94.99%59.42%-84.85%-33.64%65.9%-223.05%-167.61%-23.59%178.36%-207.18%-8.56%-18.81%70.6%81.49%-31.39%-7.07%-16.99%-50.02%236.53%49.96%48.38%222.34%147.53%-1142.72%93.13%6.06%63.33%-60.71%-
EBITDA9.69M-9.22M-844K-8.62M6.27M11.04M-7.04M6.59M23.82M26.18M-10.72M25.55M27.3M32.16M20.2M13.35M15.07M15.74M18.38M33.63M12.23M9.48M7.76M4.76M2.78M5.85M-900K-1.2M-7.9M-5.1M
EBITDA Margin %7.17%-7.15%-0.66%-8.35%5.63%10.95%-4.4%1.18%4.54%4.92%-1.98%4.74%5.73%7.28%6.36%4.82%6.33%6.67%7.71%15.97%5.27%4.62%4.04%2.6%1.46%2.79%-2.54%-3.58%-83.16%-204%
EBITDA Growth %180.34%-992.18%90.21%-237.46%-43.23%256.92%-206.8%-72.33%-9.03%344.26%-141.95%-6.42%-15.11%59.24%51.35%-11.45%-4.23%-14.38%-45.34%175.03%28.91%22.22%63.09%70.97%-52.45%750.33%25%84.81%-54.9%-
D&A (Non-Cash Add-back)9.77M8.03M8M13.18M18.06M19.87M18.84M14.6M11.97M10.68M9.07M7.09M7.11M7.29M5.62M5.31M3.36M3.14M3.2M3.26M3.2M3.47M3.71M3.5M5.43M6.07M2.2M2.1M1.1M500K
EBIT-7.04M-16.84M27.6M-46.35M-5.22M-20.85M-26M8.87M13.59M16M-16.86M18.46M20.19M34.27M21.21M9.26M8.82M13.9M15.18M30.36M9.02M6.02M4.05M1.26M-2.65M-825K-3.75M-3.3M-9M-4.3M
Net Interest Income-22.48M-21.84M-18.09M-17.58M-15.47M-8.88M-4.57M-5.08M-1.74M-1.81M-1.92M-1.51M-1.39M-1.83M-749K-390K746K1.3M000000000000
Interest Income401K0068K81K48K72K145K211K16K71K315K260K179K180K430K834K1.31M000000000000
Interest Expense22.88M21.84M18.09M17.65M15.55M8.93M4.65M5.23M1.95M1.83M1.99M1.83M1.65M2.01M929K820K88K8K000029K02.21M4.28M0000
Other Income/Expense-33.6M-21.43M18.36M-42.13M-8.9M-20.96M-4.77M-1.83M2.81M-493K934K3.01M9.73M7.4M5.71M410K746K743K2.2M1.69M-24K-4K29K-1.06M-2.19M-1.3M290K600K1.7M200K
Pretax Income-33.67M-38.67M9.51M-63.93M-20.69M-29.79M-30.64M3.64M16.4M15.01M-18.85M21.47M29.93M32.26M20.28M8.44M8.73M13.34M16.9M31.64M9M6.01M4.08M201K-4.84M-2.13M-2.7M-2.7M-7.3M-4.1M
Pretax Margin %-24.92%-30.01%7.42%-61.9%-18.59%-29.53%-19.15%0.65%3.13%2.82%-3.48%3.98%6.28%7.3%6.39%3.05%3.66%5.65%7.08%15.03%3.88%2.93%2.13%0.11%-2.53%-1.01%-7.63%-8.06%-76.84%-164%
Income Tax413K43K183K308K-5.21M-6.35M-8.77M1.52M-9.36M4.33M-7.4M7.75M10.58M9.45M7.18M4.18M4.26M5.61M3.35M2.46M396K619K1.13M00-42K100K200K-2.1M-1.4M
Effective Tax Rate %-1.23%-0.11%1.92%-0.48%25.19%21.32%28.63%41.7%-57.1%28.88%39.27%36.08%35.37%29.3%35.42%49.53%48.83%42.06%19.85%7.76%4.4%10.29%27.57%0%0%1.98%-3.7%-7.41%28.77%34.15%
Net Income-34.09M-38.72M12.01M-99.56M-116.72M-32.29M-38.19M2.12M24.83M10.59M-11.64M13.54M19.14M22.59M12.7M3.92M3.98M7.73M13.54M29.19M8.65M5.4M2.9M-1.49M-18.79M-4M-2.8M-2.9M-8.6M-4.2M
Net Margin %-25.22%-30.04%9.37%-96.41%-104.89%-32.01%-23.86%0.38%4.74%1.99%-2.15%2.51%4.02%5.11%4%1.42%1.67%3.28%5.68%13.87%3.73%2.63%1.51%-0.81%-9.84%-1.91%-7.91%-8.66%-90.53%-168%
Net Income Growth %23.66%-422.29%112.07%14.7%-261.41%15.44%-1899.76%-91.45%134.46%190.97%-185.95%-29.26%-15.24%77.91%223.88%-1.61%-48.46%-42.92%-53.61%237.41%60.14%86.28%295.02%92.08%-369.91%-42.79%3.45%66.28%-104.76%-
Net Income (Continuing)-34.09M-38.72M9.33M-64.24M-15.48M-23.44M-21.87M2.12M25.76M10.13M-11.99M13.72M19.34M22.81M13.1M4.26M4.47M8.29M13.54M29.19M9.18M5.81M2.9M201K-4.84M-2.07M-3.46M-2.9M-7.6M-2.9M
Discontinued Operations002.68M-35.33M-101.24M-8.86M-16.32M00542K00000000000000000000
Minority Interest0000000001.54M1.62M1.68M1.69M1.72M1.82M1.67M1.69M1.79M1.55M1.84M1.77M1.47M1.55M1.58M1.03M1.14M0000
EPS (Diluted)-0.91-1.270.33-3.32-3.97-1.12-1.310.070.890.38-0.430.500.710.850.490.150.150.290.501.070.320.210.11-0.08-1.15-0.25-0.28-0.22-0.77-0.54
EPS Growth %30.72%-484.85%109.94%16.37%-254.46%14.5%-1865.5%-91.66%134.21%188.37%-186%-29.58%-16.47%73.47%226.67%0%-48.28%-42%-53.27%234.38%52.38%90.91%234.47%92.89%-360%10.71%-27.27%71.43%-42.59%-
EPS (Basic)--1.270.39-3.32-3.97-1.12-1.310.070.900.39-0.430.500.710.870.500.150.150.290.521.160.350.230.11-0.08-1.15-0.25-0.28-0.23-0.77-0.54
Diluted Shares Outstanding37.48M34.82M36.66M29.96M29.47M29.29M29.16M28.61M27.91M27.65M27.15M27.34M27.12M26.63M26.13M26.63M26.63M26.75M26.93M26.56M25.66M24.61M23.56M18.17M16.37M15.8M10M13.33M11.17M7.82M
Basic Shares Outstanding37.48M34.82M30.47M29.96M29.47M29.29M29.16M28.36M27.7M27.5M27.04M26.99M26.82M25.83M25.64M26.4M26.36M26.18M26.07M25.26M24.55M23.7M21.4M18.17M16.37M15.8M10M12.61M11.17M7.82M
Dividend Payout Ratio------------------------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and operational insolvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Volatility Masks Structural Decline

As reported in recent financial filings, LFCR experienced a sharp 34.0% revenue contraction in 2026Q3, highlighting the inherent instability of its current business model as it attempts to transition away from legacy food operations while struggling to scale its core CDMO pharmaceutical services segment effectively.

The erratic revenue performance suggests that the company remains heavily dependent on lumpy milestone payments rather than a predictable base of recurring commercial supply agreements. Investors should monitor whether the recent decline reflects a permanent loss of market share or merely the timing of project-based development services.

Gross Margin Compression Reflects Inefficiency

Based on the provided income statement data, gross margins plummeted to 19.2% in 2026Q3, a significant deterioration from the 38.4% peak observed in 2025Q4, suggesting that the company is failing to achieve the necessary economies of scale within its capital-intensive aseptic fill-finish manufacturing facilities.

This margin volatility indicates that fixed costs associated with FDA-validated cleanrooms are not being adequately absorbed by current production volumes. The inability to maintain consistent margins implies that the company lacks the pricing power required to offset rising input costs or operational inefficiencies in its manufacturing processes.

Operating Leverage Remains Deeply Negative

According to the latest quarterly figures, LFCR reported an operating margin of -20.1%, confirming that the company's high fixed-cost structure continues to outpace its revenue generation, leaving little room for operational flexibility as it navigates a period of significant strategic restructuring and persistent bottom-line losses.

The persistent negative operating income suggests that the company is currently unable to leverage its existing infrastructure to drive profitability. Without a substantial increase in utilization rates for its specialized fermentation and fill-finish lines, the company may continue to face significant challenges in achieving a sustainable break-even point.

Liquidity Constraints Threaten Strategic Pivot

Financial statements indicate that with a cash position of only $8.2M against a high debt-to-equity ratio of 97.92%, the company faces a precarious liquidity profile that may force dilutive financing or fire-sale asset divestitures to sustain operations through the current period of negative net income.

Short-sellers would likely focus on the widening gap between cash burn and the company's ability to generate internal funding. The reliance on non-core asset sales to bridge the liquidity gap suggests that the company's long-term viability is contingent upon external market conditions rather than internal operational success.

LFCR — Frequently Asked Questions

Quick answers to the most common questions about buying LFCR stock.

What was Lifecore Biomedical, Inc.'s (LFCR) revenue in 2025?

For fiscal year 2025, Lifecore Biomedical, Inc. (LFCR) reported total revenue of $128.9M. This represents a 5054.7% increase compared to $2.5M in 1996.

Is Lifecore Biomedical, Inc. (LFCR) profitable?

Lifecore Biomedical, Inc. (LFCR) reported a net loss of $38.7M for the fiscal year ending 2025.

What is Lifecore Biomedical, Inc.'s operating profit margin?

Lifecore Biomedical, Inc. (LFCR) reported an operating income of $-17.2M, resulting in an operating profit margin of -13.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Lifecore Biomedical, Inc.'s gross profit and gross margin?

Lifecore Biomedical, Inc. (LFCR) generated $40.3M in gross profit for the year, representing a gross profit margin of 31.3%. This demonstrates the company's core pricing power and production efficiency.